Unicorn Nest Logo

Montagu Private Equity

www.montagu.com
Total investments

29

Average round size

43M

Portfolio companies

26

Rounds per year

0.53

Follow on index

0.10

Exits

11

Stages of investment
Private Equity
Areas of investment
TransportationSoftwareInformation TechnologyHealth CareHealth DiagnosticsWellnessManufacturingMedicalProfessional ServicesChemical Engineering

Investments analytics

Analytics

Total investments
29
Lead investments
0
Exits
11
Rounds per year
0.53
Follow on index
0.10
Investments by industry
  • Manufacturing (9)
  • Medical (5)
  • Health Care (5)
  • Health Diagnostics (3)
  • Software (3)
    • Show 39 more
Investments by region
  • United Kingdom (12)
  • United States (5)
  • Norway (1)
  • Germany (2)
  • France (2)
    • Show 5 more
Peak activity year
1997
Number of Unicorns
2
Number of Decacorns
2
Number of Minotaurs
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.
Sign Up

Quantitative data

Avg. startup age at the time of investment
44
Avg. valuation at time of investment
191M
Group Appearance index
0.24
Avg. company exit year
37
Avg. multiplicator
44.71
Strategy success index
0.40

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Upgrade

Latest deals

Company name Deal date Industry Deal stage Deal size Location
X4 Pharmaceuticals 16 Nov 2017 Biotechnology, Health Care, Pharmaceutical, Therapeutics, Clinical Trials Early Stage Venture 27M United States, Cambridge, Massachusetts
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.